anticancer/sarcoma

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 247 rezilta yo

Testing Atezolizumab in Patients >= 2 Years Old With Newly Diagnosed, Unresectable, or Metastatic Clear Cell Sarcoma or Chondrosarcoma

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVE: I. Determine the objective response rates (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 of atezolizumab in adult (>= 18 years) and pediatric/adolescent (>= 2 years) patients with clear cell sarcoma (CCS) and chondrosarcoma (CS). SECONDARY

Establishment of a Prospective Clinical-biological Database

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Liposarcomas (LPS) are soft tissue tumours of mesenchymal origin. The most common histological subtypes, represented by well differenciated Lipsarcomas (WD-LPS) and dedifferenciated (DD-LPS), are characterized by the quasi-systematic amplification of the q13-15 of chromosome 12 containing the Mdm2

Evaluation of Clinical, Radiomics and Molecular Features of Lung Metastasis in PDAC Patients (LUMACA Trial)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Radical surgical treatment of primitive PDAC, associated with adjuvant cancer treatments, is possible only in 15-20% of patients, and, to date, represents the best therapeutic strategy. Nevertheless, remote recurrence is frequent after radical surgical treatment of primitive neoplasia. Among the

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This is a first-in-human, Phase 1a/1b (dose escalation and expansion) study of BGB-3245 in participants with tumors harboring B-RAF mutations that are likely to respond to a RAF dimer inhibitor. BGB-3245 is a second-generation B-RAF inhibitor that has demonstrated potent inhibitory activity against

DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Purpose of Phase I: the main purpose: To evaluate the safety of PLD in combination with cyclophosphamide, vincristine, regenerative, and refractory solid tumors in children, including dose absorption toxicity (DLT) Secondary purpose: - determine the appropriate maximum tolerated dose (MTD) and /or

MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The hypothesis of the proposed combination is as follows: cobimetinib via MEK1/2 inhibition could modify the tumor microenvironment and improve the response of T cells against tumor cells. Therefore, the addition of cobimetinib to atezolizumab may improve immune recognition and result in improved

Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Inclusion criteria: 1. Female or male, 18 years of age or older； 2. Histologically or cytologically proven diagnosis of NSCLC； 3. Able to get tumor tissue gene testing results by lung cancer Polymerase Chain Reaction(PCR)panel kit carried out in hospital 4. Signed and dated informed

Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This will be a non-randomized stratified dual-arm open-label two-stage single-centre phase 2 trial. Patients are eligible if they are diagnosed with BRAF V600 (v-Raf murine sarcoma viral oncogene homolog B) wild-type unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and

Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A Single-arm, Open, Phase II Study of Chidamide Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Histone deacetylase inhibitor (HDACI) can inhibit many kinds of hematological tumors by inhibiting HDAC activity and other ways, showing good anti-tumor activity. Chidamide is a new chemical structure benzamide HDAC inhibitor developed independently in China. It has the selectivity of HDAC subtypes

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

KRAS is one of the most frequently mutated genes in human cancer. KRAS mutations lead to activation of cellular signaling that promotes tumor growth, and KRAS may therefore be a candidate target for anticancer therapy. This study will evaluate JNJ-74699157, a potent and specific, orally bioavailable

Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Patients with an histological diagnosis of soft-tissue sarcoma, gastrointestinal stromal tumor (GIST) or bone sarcoma (all subtypes) with ≥ 18 years old are able to be included in the study. Data registration period includes: Retrospective part: from January 2012 until June 2019 Prospective part:

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Despite constant progress in the treatment of patients with advanced solid tumors failing standard systemic treatment, there is still a high unmet medical need to develop new active anticancer drugs or therapies. Although patients with advanced melanoma have benefitted substantially from the new

A Clinicobiological Database in Metastatic Digestive Cancers

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Digestive cancers account for 30% of all cancers. The most common of these colorectal cancer (CRC) is the third most common cause of cancer in the world. In the metastatic phase, patients with digestive cancers generally benefit from medical treatment based on cytotoxic chemotherapy, which can be

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye